General FDA approves daraxonrasib for metastatic pancreatic cancer following landmark clinical trial led by Dana-FarberBy Healthcare Propulsion StaffAugust 29, 20260 The U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic…
